You are here:
Agreements >
Development Agreement > Re:
Development and License Agreement among SmithKline Beecham Corporation, doing business as GlaxoSmithKline, Glaxo Group Limited (collectively "GSK") and EPIX Pharmaceuticals, Inc. ("EPIX") dated December 11, 2006 (the "Agreement")
Dear Sir or Madam:
50 of the Top 250 law firms use our Products every day
GlaxoSmithKline
2301 Renaissance Boulevard
Mail Code RN0210
King of Prussia, PA 19406
|
Attn.:
|
|
Vice President, Business
Development
Center of Excellence for External Drug Development
|
GlaxoSmithKline
Greenford Road
Greenford, Middlesex
UB6 OHE
|
Attn.:
|
|
Vice President, Transactions
Worldwide Business Development
|
|
|
Re:
|
|
Development and License Agreement
among SmithKline Beecham Corporation, doing business as
GlaxoSmithKline, Glaxo Group Limited (collectively
“GSK”) and EPIX Pharmaceuticals, Inc.
(“EPIX”) dated December 11, 2006 (the
“Agreement”)
|
Reference is made
hereby to the Agreement. Capitalized terms used but not defined
herein shall have the meaning provided in the Agreement.
This letter
agreement is entered into to modify on a temporary basis for the
limited time period described below certain obligations of EPIX, as
set forth below, with respect to the three (3) EPIX Programs
under the Agreement. For avoidance of doubt, nothing herein shall
modify or amend and the terms of this letter agreement shall not
apply in any manner to EPIX’s obligations
|